Heart & blood Vasopressin V2 analog
Desmopressin
Regulatory status
Status at a glance
503A compounding status
Not nominated
We found no pending nomination for the 503A bulks list. Unless the substance has another legal pathway (for example, a USP monograph or use in an FDA-approved drug), 503A pharmacies generally may not compound with it.
- FDA approval
- An FDA-approved product contains this peptide
- 503B outsourcing
- Not determined
- Anti-doping (WADA)
- Not on the WADA Prohibited List
- DEA schedule
- Not a controlled substance
About peptide status
Most peptides discussed here are not FDA-approved for any use, and products labeled “research use only” are not for human use. Removal from Category 2 does not authorize compounding. PCAC votes are non-binding recommendations; FDA and HHS make the final decisions.
This is not medical or legal advice, and we do not publish dosing, sourcing or reconstitution information. Talk with a licensed clinician before using any peptide.
If you think you are having a medical emergency, call 911.
Key takeaway
Desmopressin (desmopressin acetate; brands include DDAVP and Nocdurna) is a synthetic version of the antidiuretic hormone vasopressin, engineered to concentrate urine without raising blood pressure. It treats central diabetes insipidus, bedwetting, nighttime urination, and certain bleeding disorders. It has been FDA-approved in the U.S. since 1978 and comes as tablets, a sublingual form, nasal spray, and injection.
At a glance
- What it is
- A synthetic vasopressin analog that selectively activates the V2 (antidiuretic) receptor
- Approved for
- Central diabetes insipidus, primary nocturnal enuresis, nocturia from nighttime overproduction of urine, and hemophilia A or type 1 von Willebrand disease
- Key fact
- It concentrates urine and raises clotting factor VIII without the blood-vessel effects of natural vasopressin
- Route
- Oral tablet, sublingual, nasal spray, or injection
- Evidence strength
- FDA approved
Summary
Desmopressin is a synthetic vasopressin analog approved by the FDA since 1978. Learn how it concentrates urine, its approved uses, and its main safety risk.
What is desmopressin?
Desmopressin, known generically as desmopressin acetate and sold as DDAVP and Nocdurna, is a modified copy of vasopressin, the body's antidiuretic hormone. The modifications make it act longer and focus its activity on water balance while stripping away the blood-pressure-raising effect of the natural hormone. It was approved in the United States in 1978.
How does desmopressin work?
Desmopressin selectively activates the V2 vasopressin receptor in the kidney's collecting ducts, where it increases the number of water channels (aquaporin-2) that reabsorb water back into the body. The result is more concentrated urine and less urine volume. Because the chemical changes that give desmopressin this selectivity also remove its activity at the V1 receptors on blood vessels, it does not cause the vasoconstriction that vasopressin does.
This makes it useful across several conditions. Desmopressin also has a second action unrelated to the kidney: it prompts the release of clotting factor VIII and von Willebrand factor from storage sites in blood-vessel walls. The table shows which action each use draws on:
| Condition | What desmopressin does |
|---|---|
| Central diabetes insipidus, where the body lacks vasopressin | Restores normal water conservation |
| Bedwetting and nighttime urination | Reduces overnight urine production |
| Mild hemophilia A and type 1 von Willebrand disease | Releases stored clotting factor VIII and von Willebrand factor, which is why higher doses are used to manage bleeding |
The main hazard of over-concentrating urine is dilutional low blood sodium.
Is it FDA-approved?
Editor’s note
Status: Yes. Desmopressin was first approved by the FDA in 1978, with later products including the Noctiva nasal spray (2017) and the Nocdurna sublingual tablet (2018) for nocturia. Noctiva and the Stimate nasal spray have since been discontinued in the U.S. Nocdurna carries a boxed warning about the risk of low blood sodium (hyponatremia), as Noctiva did.
Category: FDA-approved · Primary body area: Heart & blood
Yes. Desmopressin was first approved by the FDA in 1978, with later products including the Noctiva nasal spray (2017) and the Nocdurna sublingual tablet (2018) for nocturia. Noctiva and the Stimate nasal spray have since been discontinued in the U.S. Nocdurna carries a boxed warning about the risk of low blood sodium (hyponatremia), as Noctiva did.
What is desmopressin prescribed for?
Desmopressin is prescribed for central (cranial) diabetes insipidus, primary nocturnal enuresis (bedwetting), nocturia caused by nighttime overproduction of urine, and bleeding control in mild hemophilia A and type 1 von Willebrand disease. Fluid intake is usually managed carefully during treatment to avoid low sodium.
What are the side effects?
Common side effects include:
- Headache
- Nausea
- Nasal discomfort with the spray
- Flushing
More serious considerations include:
- Low blood sodium (hyponatremia), which can cause seizures if severe, the reason fluid intake is restricted and the basis of the Nocdurna boxed warning
- Caution in people at risk of fluid overload or with heart or kidney disease
Sources: FDA prescribing information for DDAVP, Nocdurna, and Noctiva. This document is educational and does not constitute medical advice.
Registered human trials
0 registered human trials on ClinicalTrials.gov that we reviewed
Sources
- [1]
Compare every peptide’s status in the peptide regulatory status database
More for Heart & blood
View all heart & blood peptides →- FDA-approved Heart & blood
Angiotensin-Ii
Angiotensin II is a natural peptide hormone and the main active signal of the renin-angiotensin system, which the body uses to raise blood pressure by tightening blood vessels. A synthetic version is FDA-approved as Giapreza, an intravenous drug given in intensive care to raise dangerously low blood pressure in adults with septic or other distributive shock. In its pivotal ATHOS-3 trial it raised blood pressure in about 70% of patients compared with 23% on placebo, though it also carries a risk of blood clots.
- In clinical trials Heart & blood
Balixafortide
Balixafortide is an investigational peptide that blocks the CXCR4 receptor, studied by Polyphor in combination with chemotherapy for metastatic breast cancer. An early single-arm trial suggested activity, but the pivotal Phase 3 trial did not show a benefit over chemotherapy alone, and development has effectively stopped. As of 2026 it is not approved.
- FDA-approved Heart & blood
Bivalirudin
Bivalirudin is a synthetic 20-amino acid peptide anticoagulant, derived in design from the leech protein hirudin, that directly and reversibly blocks thrombin, the central enzyme in blood clotting. Sold as Angiomax, it is given intravenously during coronary procedures such as angioplasty and stenting to prevent clots, including in people who cannot receive heparin. In a large trial of heart-attack patients, using it instead of heparin plus a second blood thinner reduced major bleeding and lowered 30-day death rates.
- FDA-approved Heart & blood
Desirudin
Desirudin (formerly sold as Iprivask) is a recombinant form of hirudin, the natural anticoagulant from the medicinal leech, that was used to prevent blood clots after hip replacement surgery. It directly and specifically blocks thrombin, the central enzyme of the clotting cascade. It was FDA-approved in the U.S. in 2003, but Iprivask has since been discontinued and no desirudin product is currently sold in the U.S.
- FDA-approved Heart & blood
Echinocandins
The echinocandins (caspofungin, micafungin, and anidulafungin; sold as Cancidas, Mycamine, and Eraxis) are antifungal lipopeptides that attack the fungal cell wall, a structure human cells lack. They are a preferred option for invasive Candida infections and are generally well tolerated. All three have been FDA-approved in the U.S. since the 2000s, a fourth (rezafungin, sold as Rezzayo) was approved in 2023, and all are given intravenously.
- FDA-approved Heart & blood
Eptifibatide
Eptifibatide (sold as Integrilin) is a small cyclic peptide, modeled on a molecule from rattlesnake venom, that blocks the final step of platelet clumping to prevent dangerous clots during heart attacks and stenting. It is given intravenously in acute coronary syndrome and during coronary procedures. It has been FDA-approved in the U.S. since 1998, and its main risk is bleeding.